Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

Clavé, Père; Acalovschi, Monica; Triantafillidis, John K.; Uspensky, Yu. P.; Kalaycı, Cem; Shee,; Tack, Jan; investigators, Obis study

doi:10.1111/j.1365-2036.2011.04730.x

Cited by 101 publications

(109 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another multicenter clinical trial also revealed that patients receiving otilonium bromide were less likely to present with symptom recurrence versus placebo (106).…”

Section: Efficacymentioning

confidence: 99%

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Mearin¹,

Ciriza²,

Mínguez³

et al. 2016

Rev Esp Enferm Dig

103

151

View full text Add to dashboard Cite

In this Clinical Practice Guideline we discuss the diagnostic and therapeutic approach of adult patients with constipation and abdominal complaints at the confluence of the irritable bowel syndrome spectrum and functional constipation. Both conditions are included among the functional bowel disorders, and have a significant personal, healthcare, and social impact, affecting the quality of life of the patients who suffer from them. The first one is the irritable bowel syndrome subtype, where constipation represents the predominant complaint, in association with recurrent abdominal pain, bloating, and abdominal distension. Constipation is characterized by difficulties with or low frequency of bowel movements, often accompanied by straining during defecation or a feeling of incomplete evacuation. Most cases have no underlying medical cause, and are therefore considered as a functional bowel disorder. There are many clinical and pathophysiological similarities between both disorders, and both respond similarly to commonly used drugs, their primary difference being the presence or absence of pain, albeit not in an "all or nothing" manner. Severity depends not only upon bowel symptom intensity but also upon other biopsychosocial factors (association of gastrointestinal and extraintestinal symptoms, grade of involvement, and perception and behavior variants). Functional bowel disorders are diagnosed using the Rome criteria. This Clinical Practice Guideline has been made consistent with the Rome IV criteria, which were published late in May 2016, and discuss alarm criteria, diagnostic tests, and referral criteria between Primary Care and gastroenterology settings. Furthermore, all the available treatment options (exercise, fluid ingestion, diet with soluble fiber-rich foods, fiber supplementation, other dietary components, osmotic or stimulating laxatives, probiotics, antibiotics, spasmolytics, peppermint essence, prucalopride, linaclotide, lubiprostone, biofeedback, antidepressants, psychological therapy, acupuncture, enemas, sacral root neurostimulation, surgery) are discussed, and practical recommendations are made regarding each of them.

show abstract

“…Another multicenter clinical trial also revealed that patients receiving otilonium bromide were less likely to present with symptom recurrence versus placebo (106).…”

Section: Efficacymentioning

confidence: 99%

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Mearin¹,

Ciriza²,

Mínguez³

et al. 2016

Rev Esp Enferm Dig

103

151

View full text Add to dashboard Cite

show abstract

“…Therefore, this class of agents can counteract three mechanisms that contribute to chronic diarrhea. Clinical trials show greatest effect of otilonium on abdominal sensation rather than bowel dysfunction in patients with IBS (47,48). A small trial using crossover design showed similar efficacy of solifenacin and ramosetron (49).…”

Section: Chronic Diarrheamentioning

confidence: 99%

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Camilleri¹

2013

J. Clin. Invest.

View full text Add to dashboard Cite

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. IntroductionGastrointestinal motility and functional disorders result in either abnormal propulsion of content or excessive sensation of normal or abnormal functions in different regions of the gut. These conditions constitute about 40% of referrals to gastroenterologists, and they result in significant disease burden. Advances in clinical management of these disorders are based on understanding the basic mechanisms involved in sensorimotor and secretory functions, coupled with clinical investigation and trial methodology.The most frequent gastrointestinal motility and functional disorders are esophagitis, gastroparesis, chronic diarrhea, chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and visceral pain. This review summarizes the pathophysiology, lists commonly used current medications, and focuses on pharmacological agents in development for each disorder. At present, several approved medications relieve constipation and diarrhea; the major unmet needs are in gastroparesis, OIC, and visceral pain.

show abstract

“…A randomised, double-blind clinical trial demonstrated a lower rate of symptom relapse (P=0.009) and higher relapse-free probability (P=0.038) in patients treated with otilonium bromide for 15 weeks compared with patients treated with placebo. 34 A 2-year study demonstrated a significant improvement in abdominal pain, abdominal distension, and bowel movements in patients treated with otilonium bromide, compared with a high-roughage diet. 35 Statement 19: Antispasmodics are also commonly prescribed in combination with antidiarrhoeal drugs or laxatives.…”

Section: Rome III Rome Ivmentioning

confidence: 99%

“…Nearly all were mild to moderate (99% in the otilonium bromide group and 98% in the placebo group) and were considered unrelated to the study treatment (92% in the otilonium bromide group and 94% in the placebo group). 34 Statement 18: Further study is warranted to establish an optimal treatment period for otilonium bromide.…”

Section: Rome III Rome Ivmentioning

confidence: 99%

The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements

Chan

et al. 2017

Hong Kong Med J

View full text Add to dashboard Cite

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

Abstract: SUMMARY Background

Cited by 101 publications

References 23 publications

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements

Contact Info

Product

Resources

About